Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Cancer Registry of Rhineland-Palatinate, Institute of Medical Biostatistics, Epidemiology, and Informatics, Mainz, Germany.
Int J Cancer. 2018 Jul 15;143(2):324-332. doi: 10.1002/ijc.31322. Epub 2018 Mar 5.
Hepatobiliary tract cancers (HBTCs) are a heterogeneous group of cancers with high mortality. Because most of these cancers, with the exception of hepatocellular carcinoma (HCC), are rare, few data are available concerning the population level survival expectations of patients with HBTC. Here, we describe survival of patients with HBTC in Germany with comparison to survival in the US. Therefore, data were extracted from 12 databases in Germany and the Surveillance, Epidemiology and End Results (SEER13) database in the US. Period analysis and modeled period analysis were used to calculate 5-year relative survival estimates for patients with HBTC diagnosed from 1997 to 2013. HCC was the most common HBTC in each database, accounting for over 1/3 of HBTC in Germany and about half of cases in the US. Overall age adjusted 5-year relative survival for HBTC in 2006-2013 was 19.1% in Germany and 20.6% in the US. Five-year relative survival increased by 3.8% units in Germany and 4.5% units in the US between 2002-2005 and 2010-2013. Five-year relative survival for individual types of HBTC ranged from 9.8% in Germany and 2.9% in the US for not otherwise specified biliary tract cancers to 44.4% and 50.1%, respectively, in Germany and the US for duodenal cancers. In conclusion, survival for HBTC remains poor in both Germany and the US, although a small increase in survival in the past decade was observed. Further work to find better treatment options for HBTC is needed to improve survival.
肝胆管癌（HBTC）是一组具有高死亡率的异质性癌症。由于除肝细胞癌（HCC）外，大多数此类癌症都很少见，因此有关 HBTC 患者的人群水平生存预期的数据很少。在这里，我们描述了德国 HBTC 患者的生存情况，并与美国的生存情况进行了比较。因此，从德国的 12 个数据库和美国的监测，流行病学和最终结果（SEER13）数据库中提取了数据。使用期间分析和模型期间分析来计算 1997 年至 2013 年间诊断出的 HBTC 患者的 5 年相对生存率。在每个数据库中，HCC 是最常见的 HBTC，占德国 HBTC 的 1/3 以上，占美国病例的一半左右。2006-2013 年，德国 HBTC 的总体年龄调整后 5 年相对生存率为 19.1％，而美国为 20.6％。2002-2005 年至 2010-2013 年期间，德国和美国的 5 年相对生存率分别增加了 3.8％和 4.5％。HBTC 各类型的 5 年相对生存率范围从德国的 9.8％和美国的 2.9％（未特指的胆管癌）到德国的 44.4％和美国的 50.1％（十二指肠癌）。总之，尽管过去十年的生存率略有提高，但德国和美国的 HBTC 生存率仍然很差。需要进一步努力寻找更好的 HBTC 治疗选择，以提高生存率。
